HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801

Integrated Synthesis-to-Clinic Program Will Support HTD1801's Clinical Development and Regulatory Submission Package ROCKVILLE, Md., SHENZHEN, China and NOTTINGHAM, England, Dec. 15, 2022

Related Keywords

China ,Shenzhen ,Guangdong ,Liping Liu ,Kostenloser Wertpapierhandel ,Mark Egerton ,Prnewswire Hightide Therapeutics Inc ,National Major New Drug Innovation Program ,Drug Administration ,Quotient Sciences ,Clinical Development ,Regulatory Submission ,Mytide Therapeutics ,Fast Track ,Orphan Drug ,National Major New Drug Innovation ,Hightide ,Herapeutics ,Quotient ,Ciences ,Nnounce ,Agreement ,Conduct ,Human ,Dme ,Program ,Td1801 ,